Agios

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Agios and other ETFs, options, and stocks.

About AGIO

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology.

CEO

Brian M. Goff

CEOBrian M. Goff

Employees

540

Employees540

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2007

Founded2007

Employees

540

Employees540

AGIO Key Statistics

Market cap

2.03B

Market cap2.03B

Price-Earnings ratio

-4.71

Price-Earnings ratio-4.71

Dividend yield

—

Dividend yield—

Average volume

1.23M

Average volume1.23M

High today

$34.45

High today$34.45

Low today

$33.50

Low today$33.50

Open price

$33.90

Open price$33.90

Volume

1.80M

Volume1.80M

52 Week high

$46.00

52 Week high$46.00

52 Week low

$22.24

52 Week low$22.24

Stock Snapshot

The current Agios(AGIO) stock price is $34.16, with a market capitalization of 2.03B. The stock trades at a price-to-earnings (P/E) ratio of -4.71.

During the trading session on 2026-06-19, Agios(AGIO) shares reached a daily high of $34.45 and a low of $33.50. At a current price of $34.16, the stock is +2.0% higher than the low and still -0.8% under the high.

Trading activity shows a volume of 1.8M, compared to an average daily volume of 1.23M.

The stock's 52-week range extends from a low of $22.24 to a high of $46.00.

AGIO News

TipRanks 23h

Agios Pharma Shareholders Expand Equity Plan, Reelect Directors

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

TipRanks 1d

Agios Targets Transfusion Burden in Sickle Cell Disease With New Phase 3 Bet on Mitapivat

Agios Pharmaceuticals (AGIO) announced an update on their ongoing clinical study. Claim 55% Off TipRanks Unlock powerful investing tools and data-driven insight...

Simply Wall St 2d

Agios Pharmaceuticals Stock Could Be 22% Undervalued After RISE UP Phase 3 Data

Agios Pharmaceuticals (AGIO) stock is back in focus after the company shared detailed 52 week data from its RISE UP Phase 3 trial of mitapivat in sickle cell di...

Analyst ratings

70%

of 10 ratings

Buy

70%

Hold

30%

Sell

More AGIO News

Simply Wall St 4d

Agios Pharmaceuticals Is Up 7.4% After Mitapivat RISE UP Data in Sickle Cell Disease - Has The Bull Case Changed?

Agios Pharmaceuticals recently presented detailed 52-week Phase 3 RISE UP data for its oral PK activator mitapivat in adults with sickle cell disease, showing s...

TipRanks 4d

Agios Pharmaceuticals price target raised to $54 from $50 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $54 from $50 and keeps a Buy rating on the shares. The company over the weeken...

TipRanks 5d

Agios Pharmaceuticals presented results from Phase 3 trial of mitapivat

Agios Pharmaceuticals (AGIO) presented detailed results from the 52-week double-blind period of the global RISE UP Phase 3 trial of mitapivat. These efficacy an...

People also own

Based on the portfolios of people who own AGIO. This list is generated using Robinhood data, and it’s not a recommendation.

Palantir Technologies

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.